Abstract
New structural modifications of the marine shell-less mollusk peptide constituent dolastatin 10 (1) have been synthesized, and evaluated against a variety of cancer cell lines and for their ability to inhibit tubulin polymerization. A number of useful structure-activity relationships were uncovered. The most important observation was that the dolaphenine unit of dolastatin 10 could be satisfactorily replaced with a phenethylamine. Peptide 11C, designated auristatin PE, was found to exhibit inhibition of cancer cell growth and tubulin assembly comparable to that of dolastatin 10.
Author supplied keywords
Cite
CITATION STYLE
Pettit, G. R., Srirangam, J. K., Barkoczy, J., Williams, M. D., Durkin, K. P. M., Boyd, M. R., … Chapuis, J. C. (1995). Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications. Anti-Cancer Drug Design, 10(7), 529–544.
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.